Form 4: Windtree Therapeutics CEO Acquires Shares in Open Market Purchase
SEC Form 4
Craig Fraser, CEO of Windtree Therapeutics, recently purchased 5,431 shares of the company's common stock at a price of $0.9099 per share.
Summary
- On October 8, 2024, Craig Fraser, the President and CEO of Windtree Therapeutics, acquired 5,431 shares of common stock.
- The purchase price was $0.9099 per share.
- Following the transaction, Fraser directly owns 8,638 shares of Windtree Therapeutics.
- Fraser also indirectly owns shares through a trust and the company's 401(k) plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive sign, but the filing itself is a routine regulatory document.
Positives
- The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive signal, suggesting that a company's management believes the stock is undervalued. However, it's important to consider the size of the purchase relative to the executive's overall holdings and the company's market capitalization.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| April 19, 2024 | 1-for-18 reverse stock split effective date. |
| October 08, 2024 | Date of common stock purchase by Craig Fraser. |
| October 09, 2024 | Date of signature on the Form 4 filing. |
Keywords
Windtree Therapeutics, Craig Fraser, stock purchase, Form 4, CEO, WINT, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.